Tg Therapeutics, Inc. financial data

Symbol
TGTX on Nasdaq
Industry
Pharmaceutical Preparations
Location
2 Gansevoort Street, 9 Th Floor, New York, NY
State of incorporation
DE
Fiscal year end
December 31
Former names
MANHATTAN PHARMACEUTICALS INC (to 4/27/2012), ATLANTIC TECHNOLOGY VENTURES INC (to 3/10/2003), ATLANTIC PHARMACEUTICALS INC (to 2/4/2000)
Latest financial report
10-K - Q4 2024 - Mar 3, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 446 % +6.89%
Quick Ratio 83.5 % +57.7%
Debt-to-equity 158 % -9.59%
Return On Equity -354 %
Return On Assets 4.83 % +2.77%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 157M shares +1.64%
Common Stock, Shares, Outstanding 156M shares +2.91%
Entity Public Float 2.5B USD -26.5%
Common Stock, Value, Issued 156K USD +3.31%
Weighted Average Number of Shares Outstanding, Basic 145M shares +2.37%
Weighted Average Number of Shares Outstanding, Diluted 161M shares +3.11%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 329M USD +40.8%
Research and Development Expense 94.3M USD +23.8%
Costs and Expenses 287M USD +34.8%
Operating Income (Loss) 41.9M USD +103%
Nonoperating Income (Expense) -16.3M USD -116%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 25.6M USD +95.9%
Income Tax Expense (Benefit) 2.21M USD
Net Income (Loss) Attributable to Parent 23.4M USD +84.5%
Earnings Per Share, Basic 0.16 USD/shares +77.8%
Earnings Per Share, Diluted 0.02 USD/shares -97.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 180M USD +93.6%
Cash, Cash Equivalents, and Short-term Investments 311M USD +43%
Accounts Receivable, after Allowance for Credit Loss, Current 129M USD +153%
Inventory, Net 110M USD +177%
Other Assets, Current 15.7M USD +65.1%
Assets, Current 566M USD +78.1%
Property, Plant and Equipment, Net 66K USD -72.2%
Operating Lease, Right-of-Use Asset 7.15M USD -11.2%
Goodwill 799K USD 0%
Other Assets, Noncurrent 2.07M USD -10.2%
Assets 578M USD +75.3%
Liabilities, Current 90.7M USD +68.8%
Operating Lease, Liability, Noncurrent 8.13M USD -11.9%
Liabilities 355M USD +110%
Retained Earnings (Accumulated Deficit) -1.53B USD +1.51%
Stockholders' Equity Attributable to Parent 222M USD +38.5%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 40.5M USD -68.7%
Liabilities and Equity 578M USD +75.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -8.21M USD +86.3%
Net Cash Provided by (Used in) Financing Activities 25.2M USD
Net Cash Provided by (Used in) Investing Activities -9.26M USD -50%
Common Stock, Shares Authorized 190M shares +8.57%
Common Stock, Shares, Issued 156M shares +3.13%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -17.5M USD +57.3%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 181M USD +92.3%
Interest Paid, Excluding Capitalized Interest, Operating Activities 2.45M USD +40%
Deferred Tax Assets, Valuation Allowance 415M USD -0.89%
Deferred Tax Assets, Gross 415M USD -0.89%
Operating Lease, Liability 9.29M USD -13%
Depreciation 68K USD -10.5%
Lessee, Operating Lease, Liability, to be Paid 12.6M USD -15.9%
Operating Lease, Liability, Current 1.16M USD -20%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.08M USD -0.95%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.1M USD -12.1%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3.35M USD -23%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.91M USD -8.03%
Deferred Tax Assets, Operating Loss Carryforwards 294M USD -7.23%
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.83M USD -4.5%
Operating Lease, Payments 600K USD
Additional Paid in Capital 1.76B USD +2.76%
Amortization of Intangible Assets 53K USD 0%
Depreciation, Depletion and Amortization 29K USD -57.4%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 42.5M USD +12.1%
Interest Expense 12.1M USD +16.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%